Prasinezumab could have a long-term beneficial effect on Parkinson’s disease
medicine Friday, November 1, 2024 Basel – The alpha-synuclein antibody prasinezumab, which was unable to stop the progression of Parkinson’s disease in a randomized phase 2 study, could still have a disease-modifying effect in the